Vaxican
Next generation immunotherapeutics
About us
Vaxican is a startup raised by a group of people with academic background.
In 2020 we have been a member of MIT Acceleration Programme and since then we have developed and expanded in two directions.
First, where our mission is to create synergistic immunotherapies that really transform the way we treat some of the most devastating diseases we have faced today, especially in cancer.
The second, under the shield of Vaxican Genomics, where we provide the services in the field of next generation sequencing (Oxford Nanopore Technology official service provider) of full genomes of microorganism and targeted sequencing of human and animal DNA/RNA.
Research & Development
Cancer is leading cause of death worldwide, accounting for nearly 10mln deaths in 2020, or nearly one in six deaths.
Immunotherapies have been used to treat various types of cancer for a decade or more, but it is still the case of the future to cure it. In spite of some remarkable successes and billions of dollars spent on research and development, immunotherapy is used mainly for hopeless cases of stage III and stage IV diseases.
We wanted to teach the patient’s immune system how to recognize cancer cells and stimulate humoral as well as cellular response.
Team
Martyna Krejmer-Rąbalska, PhD
Medical Laboratory Scientist Science/Technology
Martyna Krejmer-Rąbalska, PhD
Medical Laboratory Scientist Science/Technology
Broad scientific experience in virology and virus-like particles (VLP) production. Working with mammalian and insect cell cultures. Researcher at the Department of Recombinant Vaccines (University of Gdansk).
Łukasz Rąbalski, PhD
CEO, Science/Technology
Łukasz Rąbalski, PhD
CEO, Science/Technology
Assistant Professor at Department of Recombinant Vaccines (University of Gdansk). Broad experience as principal investigator in various virological projects. First to obtain the whole genetic sequence of the SARS-CoV-2 coronavirus isolated from the Polish patient (published in the international GISAID database).
Krzysztof Łepek, PhD
COO, Science/Operations
Krzysztof Łepek, PhD
COO, Science/Operations
Broad scientific experience in virology, epidemiology of human and animal viruses. Working with mammalian and insect cell cultures. University of Gdansk origins.
Maciej Kosiński
Sequencing Process Manager, Science/Technology
Maciej Kosiński
Sequencing Process Manager, Science/Technology
Broad scientific experience in virology, epidemiology of human and animal viruses. Experience with long and short reads sequencing.
Mateusz Sagan, MBA
Strategy/Funding/Partnering
Mateusz Sagan, MBA
Strategy/Funding/Partnering
20+ years of executive experience in the corporate business. Disruptive Innovations Funding & Mentoring (incl. MIT Acc. Program). €20m+ funding obtained for early stage Biotech/HealthTech companies. 10+ Corporate Partnerships.
Aurelia Schweda, MSc
R&D Laboratory Manager, Science/Technology
Aurelia Schweda, MSc
R&D Laboratory Manager, Science/Technology
Research development of new projects. Experience in project and process management. Extensive experience in production of VLPs.
Contact us
